Tigecycline: a critical safety review

Kaewpoowat, Quanhathai; Ostrosky-Zeichner, Luis

doi:10.1517/14740338.2015.997206

Cited by 76 publications

(58 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As with carbapenems and colistin, outcomes are poor with tigecycline monotherapy but improved when tigecycline is combined with another agent [76, 78, 91]. However, there are emerging data suggesting increased mortality in patients treated with tigecycline for any indication, the etiology of which is not well understood but thought to be most likely related to poorly sustained serum concentrations; as a result, the FDA has issued a black box warning for this agent [56, 92]. In pediatric settings, experience with tigecycline is limited to case reports, and along with the potential for increased mortality, association with enamel hypoplasia, tooth discoloration, and availability of other agents should limit its use to situations when other treatment options have been exhausted [40, 41, 48, 49, 81, 93].…”

Section: Treatment Of Infections Due To Crementioning

confidence: 99%

Carbapenem-Resistant Enterobacteriaceae Infections in Children

Chiotos

Han

Tamma

2015

Curr Infect Dis Rep

View full text Add to dashboard Cite

Carbapenem-resistant Enterobacteriaceae (CRE) are an emerging global public health threat. Infections due to CRE are associated with significant morbidity and mortality. Few therapeutic options are available for treatment of these infections, and optimal antibiotic treatment regimens are unclear. Along with the rapidly increasing prevalence of CRE in the United States and worldwide, several studies have described the epidemiology of CRE in the adult population. While CRE is now also reported sporadically in children, there is a significant lack of data on the epidemiology, risk factors, treatment, and outcomes in this population. This article provides a comprehensive review of what is known to date about CRE, including clinical and molecular epidemiology, microbiologic diagnosis, antibiotic treatment options, and outcomes. In particular, this review will focus on the available data on CRE in the pediatric population.

show abstract

Section: Treatment Of Infections Due To Crementioning

confidence: 99%

Carbapenem-Resistant Enterobacteriaceae Infections in Children

Chiotos

Han

Tamma

2015

Curr Infect Dis Rep

View full text Add to dashboard Cite

show abstract

“…The most common type of lung cancer is nonsmall cell lung cancer (NSCLC), which accounts for 80% of lung cancers and presents different subtypes: squamous cell, carcinoma, adenocarcinoma, and large cell carcinoma [1][2][3]. The most common type of lung cancer is nonsmall cell lung cancer (NSCLC), which accounts for 80% of lung cancers and presents different subtypes: squamous cell, carcinoma, adenocarcinoma, and large cell carcinoma [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function

Jia

Chen

et al. 2016

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Nonsmall cell lung cancer (NSCLC) is the most common type of lung cancer with a high mortality rate and still remains therapeutically a challenge. A strategy to target NSCLC is to identify agents that are effective against NSCLC cells while sparing normal cells. We show that tigecycline, an FDA-approved antibiotic drug, preferentially targets NSCLC cells. Tigecycline is effective in inhibiting proliferation and inducing apoptosis of multiple cell lines derived from two common NSCLC subtypes: adenocarcinoma and squamous cell carcinoma. Tigecycline also dose-dependently inhibits colony formation of NSCLC subpopulation of cells with highly proliferative and invasive properties. Compared to NSCLC cells, tigecycline affects proliferation and survival of normal fibroblast cells significantly to a less extent. More importantly, tigecycline significantly inhibits NSCLC tumor growth through decreasing proliferation and increasing apoptosis of tumor cells in vivo. Tigecycline significantly inhibits mitochondrial respiration, mitochondrial membrane potential, and ATP levels and increases reactive oxygen species (ROS), suggesting that tigecycline impairs mitochondrial functions. Our study suggests that tigecycline may be a useful therapeutic agent, and inhibiting mitochondrial functions may represent a new targeted therapy for NSCLC.

show abstract

“…Tigecycline is administered by slow intravenous infusion (for 30 to 60 minutes) every 12 hours. It is primarily eliminated as an unchanged form in the feces and secondarily eliminated by the kidneys [43,44]. Although dose reduction is required in severe hepatic impairment, no adjustment is necessary for patients with renal insufficiency or for those undergoing hemodialysis.…”

Section: Tigecyclinementioning

confidence: 99%

Management of Antibiotic-Resistant Acute Pyelonephritis

Lee

Yoon

2017

Urogenit Tract Infect

View full text Add to dashboard Cite

Acute pyelonephritis (APN) is a common urinary tract infection that affects a large proportion of women. Although antimicrobial therapy is a successful treatment in most cases, empirically, antibiotic resistance has emerged as a serious issue, including high resistance rate of fluoroquinolone and the advent of extendedspectrum -lactamase (ESBL)-producing organisms. Several agents can be considered for the management of antibiotic resistant APN. Fosfomycin trometamol is effective in treating ESBL-producing bacterial infection. Oral trimethoprim/sulfamethoxazole, -lactam agents, such as cephalosporin, and fluoroquinolone can be regarded as appropriate agents if pathogen is susceptible. Carbapenem, such as imipenem, meropenem, and doripenem, is one of the best and widely used agents for treating antibiotic resistant APN. However, there have recently been concerns regarding the increased rates of resistance to carbapenems. Daptomycin, linezolid, and tigecycline can be considered as solutions to antibiotic resistant organisms. Antibiotic resistant APN should be treated as other systemic infections to prevent antibiotic overuse with proper treatment duration considering carbapenem-saving strategy.

show abstract

Tigecycline: a critical safety review

Cited by 76 publications

References 49 publications

Carbapenem-Resistant Enterobacteriaceae Infections in Children

Carbapenem-Resistant Enterobacteriaceae Infections in Children

Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function

Management of Antibiotic-Resistant Acute Pyelonephritis

Contact Info

Product

Resources

About